TABLE 2.
Association between plasma miR‐192‐5p after NAC and clinicopathological factors in EC with NAC
| Variables | n = 69 | Plasma miR‐192‐5p after NAC | p‐value a | ||
|---|---|---|---|---|---|
| Low (≤3.5) | High (>3.5) | ||||
| n = 41 | n = 28 | ||||
| Age | >65 | 42 | 24 (57%) | 18 (43%) | 0.630 |
| ≤65 | 27 | 17 (63%) | 10 (37%) | ||
| Sex | Male | 56 | 31 (55%) | 25 (45%) | 0.153 |
| Female | 13 | 10 (77%) | 3 (23%) | ||
| Tumor size (mm) | >40 | 31 | 20 (65%) | 11 (35%) | 0.436 |
| ≤40 | 38 | 21 (55%) | 17 (45%) | ||
| Regimen of NAC | DCF | 42 | 24 (57%) | 18 (43%) | 0.630 |
| FP | 27 | 17 (63%) | 10 (37%) | ||
| Pathological T factor b | T3,4 | 36 | 25 (69%) | 11 (31%) | 0.076 |
| T0‐2 | 33 | 16 (48%) | 17 (52%) | ||
| Pathological N factor b | N1‐4 | 33 | 23 (70%) | 10 (30%) | 0.096 |
| N0 | 36 | 18 (50%) | 18 (50%) | ||
| Lymphatic invasion b | + | 18 | 10 (56%) | 8 (44%) | 0.697 |
| − | 51 | 31 (61%) | 20 (39%) | ||
| Venous invasion b | + | 26 | 18 (69%) | 8 (31%) | 0.196 |
| − | 43 | 23 (53%) | 20 (47%) | ||
| Pathological stage b | 2, 3 | 40 | 27 (67%) | 13 (33%) | 0.138 |
| 0, 1 | 29 | 14 (48%) | 15 (52%) | ||
| Pathological grade b | 1, 2 | 59 | 38 (65%) | 21 (35%) | 0.040 |
| 3 | 10 | 3 (30%) | 7 (70%) | ||
Abbreviations: DCF, docetaxel + cisplatin + 5‐FU; FP, cisplatin + 5‐FU; NAC, neoadjuvant chemotherapy.
a
p‐values were calculated using the chi‐squared test.
b
According to the 11th edition of the Japanese Classification of Esophageal Cancer.